OCUFLOX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ocuflox, and when can generic versions of Ocuflox launch?
Ocuflox is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in OCUFLOX is ofloxacin. There are seventy-eight drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the ofloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ocuflox
A generic version of OCUFLOX was approved as ofloxacin by CHARTWELL RX on September 2nd, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OCUFLOX?
- What are the global sales for OCUFLOX?
- What is Average Wholesale Price for OCUFLOX?
Summary for OCUFLOX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 167 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,165 |
| Drug Prices: | Drug price information for OCUFLOX |
| What excipients (inactive ingredients) are in OCUFLOX? | OCUFLOX excipients list |
| DailyMed Link: | OCUFLOX at DailyMed |
Recent Clinical Trials for OCUFLOX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Montefiore Medical Center | Phase 3 |
| Stanford University | Phase 4 |
| Oregon Health and Science University | Phase 4 |
Pharmacology for OCUFLOX
| Drug Class | Quinolone Antimicrobial |
US Patents and Regulatory Information for OCUFLOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | OCUFLOX | ofloxacin | SOLUTION/DROPS;OPHTHALMIC | 019921-001 | Jul 30, 1993 | AT | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OCUFLOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Allergan | OCUFLOX | ofloxacin | SOLUTION/DROPS;OPHTHALMIC | 019921-001 | Jul 30, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Allergan | OCUFLOX | ofloxacin | SOLUTION/DROPS;OPHTHALMIC | 019921-001 | Jul 30, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OCUFLOX
See the table below for patents covering OCUFLOX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1241599 | UTILISATION EN OPHTALMOLOGIE DE LA NORFLOXACINE ET DES ANTIBIOTIQUES APPARENTES (OPHTHALMIC USE OF NORFLOXACIN AND RELATED ANTIBIOTICS) | ⤷ Sign Up |
| Australia | 567979 | ⤷ Sign Up | |
| New Zealand | 210104 | OPHTHALMIC ANTIBIOTIC COMPOSITIONS | ⤷ Sign Up |
| Denmark | 204488 | ⤷ Sign Up | |
| Spain | 537584 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OCUFLOX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1429780 | SPC/GB12/058 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 1429780 | 132013902137451 | Italy | ⤷ Sign Up | PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106 |
| 0206283 | C980016 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
| 0206283 | 98C0041 | Belgium | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 |
| 0413455 | 98C0040 | Belgium | ⤷ Sign Up | PRODUCT NAME: ALATROFLOXACIN; NAT. REGISTRATION NO/DATE: EU/1/98/060/001 19980327; FIRST REGISTRATION: CH 54484 19980327 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
